Drugs / VES001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06705192 | Dec 2024 → Aug 2025 | frontotemporal dementia | Mads Kjolby | Completed | No outcome recorded |
| Phase 1 | NCT06226064 | Oct 2023 → Jul 2024 | frontotemporal dementia | Vesper Biotechnologies ApS | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-10-01 | Vesper Biotechnologies ApS | Results VESPER BIO ANNOUNCES POSITIVE PHASE IB/IIA TOPLINE RESULTS FOR LEAD CANDIDATE VES001 FOR FRONTOTEMPORAL DEGENERATION vesperbio.com ↗ |
| 2024-09-01 | Vesper Biotechnologies ApS | Results VESPER BIO ANNOUNCES SUCCESSFUL PHASE I STUDY FOR POTENTIALLY DISEASE-MODIFYING TREATMENT FOR FRONTOTEMPORAL DEMENTIA. vesperbio.com ↗ |
| 2024-05-01 | Vesper Biotechnologies ApS | Results VESPER BIO ANNOUNCES COMPLETION OF SINGLE ASCENDING DOSE STAGE IN TRIAL OF ITS LEAD CANDIDATE VES001. vesperbio.com ↗
Data returned from this study (NCT06226064) demonstrate the safety and tolerability of VES001 across the full range of doses tested and show it has excellent pharmacokinetics and distribution to relevant parts of the brain. |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VES001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06705192 ↗ |
| Route | Oral | “VES001 is an oral, blood brain barrier penetrating ligand of sortilin.” NCT06226064 ↗ |